Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities researchers at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Krystal Biotech in a research note issued to investors on Monday, November 4th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $7.02 for the year, up from their previous estimate of $6.47. HC Wainwright currently has a "Buy" rating and a $221.00 price target on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $2.88 per share.
KRYS has been the subject of a number of other research reports. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. Stifel Nicolaus raised their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a report on Wednesday, September 11th. Citigroup boosted their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a report on Tuesday. Evercore ISI lifted their target price on Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a research report on Monday, August 12th. Finally, William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $197.00.
Get Our Latest Analysis on KRYS
Krystal Biotech Stock Up 5.0 %
Shares of NASDAQ KRYS traded up $8.68 on Wednesday, hitting $183.09. The company had a trading volume of 609,984 shares, compared to its average volume of 181,472. Krystal Biotech has a 12-month low of $93.95 and a 12-month high of $219.34. The firm has a market capitalization of $5.26 billion, a P/E ratio of 103.44 and a beta of 0.82. The business has a 50 day moving average of $181.39 and a two-hundred day moving average of $180.25.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same quarter in the previous year, the business posted ($0.67) EPS. The business's quarterly revenue was up 879.9% on a year-over-year basis.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the stock. Huntington National Bank boosted its position in shares of Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company's stock worth $104,000 after buying an additional 283 shares during the period. KBC Group NV raised its stake in Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company's stock valued at $117,000 after acquiring an additional 132 shares in the last quarter. Pier 88 Investment Partners LLC boosted its position in Krystal Biotech by 5.1% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 3,530 shares of the company's stock worth $643,000 after acquiring an additional 170 shares during the period. Oppenheimer Asset Management Inc. bought a new position in shares of Krystal Biotech in the third quarter worth $235,000. Finally, Prime Capital Investment Advisors LLC raised its stake in shares of Krystal Biotech by 93.1% during the third quarter. Prime Capital Investment Advisors LLC now owns 2,591 shares of the company's stock valued at $472,000 after purchasing an additional 1,249 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.
Insider Transactions at Krystal Biotech
In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 14.10% of the company's stock.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Articles
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
